- Clearmind Medicine (CSE:CMND) revealed results from its treatment targeting cocaine addiction
- The company stated it had used novel psychedelic-derived therapeutics to achieve positive results in addiction treatment targeting cocaine addiction
- The treatments centered on the company’s psychedelic molecule, MEAI, a novel proprietary psychedelic treatment used to treat various conditions
- Clearmind Medicine opened at C$7.70 per share
Clearmind Medicine (CSE:CMND) revealed results from its treatment targeting cocaine addiction.
In a news release, the company stated it had used novel psychedelic-derived therapeutics to achieve positive results in addiction treatment targeting cocaine addiction. The treatments centered on the company’s psychedelic molecule, MEAI.
MEAI is a novel proprietary psychedelic treatment used to treat various conditions and the trial was led by professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel.
“These results offer a beacon of hope, demonstrating the potential efficacy of MEAI in reducing cocaine-related conditions. Our unique psychedelic compound has shown remarkable results in pre-clinical trials for cocaine addiction,” Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, said in a statement. “These promising results from our MEAI-based treatment offer a potential paradigm shift in how we approach the complex challenge of cocaine addiction, an addiction for which no dedicated treatment has yet been developed.”
This research resulted in a patent application in the United States that is part of the company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
Clearmind Medicine is a psychedelic pharmaceutical biotech company focused on discovering and developing novel psychedelic treatments for health problems such as alcohol use disorder. The company’s intellectual portfolio also includes 15 patent families.
Clearmind Medicine was up nearly 50 per cent in early Tuesday trading and opened at C$7.70 per share. Though Clearmind stock is down 29.47 per cent over the past month, it has grown 75.71 per cent in the past week.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.